Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14379745 | 1.00 | MAPK1 (0.39) | MAPK1KMT2AYEATS4KDM4ECYP1A2 | |
| SCHEMBL12737778 | 0.97 | MAPK1 (0.41) | MAPK1KMT2AYEATS4KDM4ECYP1A2 | |
| SCHEMBL25968930 | 0.89 | NPC1 (0.38) | MAPK1KMT2AYEATS4KDM4ECYP1A2 | |
| SCHEMBL21184650 | 0.87 | HSD17B1 (0.50) | CYP2C9CYP2C19HSD17B1HSD17B2APP | |
| SCHEMBL20718123 | 0.86 | KDM4E (0.41) | MAPK1KMT2AYEATS4KDM4ECYP1A2 | |
| SCHEMBL23718397 | 0.85 | MAPK1 (0.35) | MAPK1KMT2AYEATS4KDM4ECYP1A2 | |
| SCHEMBL13879207 | 0.85 | NPC1 (0.39) | MAPK1KMT2AYEATS4KDM4ECYP1A2 | |
| SCHEMBL17538763 | 0.85 | ALDH1A1 (0.34) | MAPK1KMT2AYEATS4KDM4ECYP1A2 | |
| SCHEMBL17523391 | 0.85 | DPP4 (0.55) | MAPK1KMT2AKDM4ECYP1A2ALDH1A1 | |
| SCHEMBL19236817 | 0.85 | ALDH1A1 (0.34) | MAPK1KMT2AYEATS4KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400253-B1 | DITHIOPHENETHIADIAZOLE SEMICONDUCTORS AND RELATED DEVICES | FLEXTERRA INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-20170096523-A1 | Polymeric Semiconductors and Related Devices | USINVEST LLC | 2017-04-06 | — | — | US | disclosed |
| US-20170044309-A1 | PREPARATION OF HIGH MOLECULAR WEIGHT POLYMERS BY DIRECT ARYLATION AND HETEROARYLATION | UNIVERSITE LAVAL (CA) | 2017-02-16 | — | — | US | disclosed |
| US-9505876-B2 | Preparation of high molecular weight polymers by direct arylation and heteroarylation | UNIVERSITE LAVAL (CA) | 2016-11-29 | — | — | US | disclosed |
| US-9227986-B2 | Diarylethene compounds and uses thereof | SWITCH MATERIALS, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-9227986-B2 | Diarylethene compounds and uses thereof | SWITCH MATERIALS, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8968715-B2 | Drug delivery systems for photodynamic therapy | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-03 | — | — | US | disclosed |
| US-20140371409-A1 | PREPARATION OF HIGH MOLECULAR WEIGHT POLYMERS BY DIRECT ARYLATION AND HETEROARYLATION | UNIVERSITE LAVAL (CA) | 2014-12-18 | — | — | US | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062384-A2 | REDUCED FLUENCE RATE PDT | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062385-A2 | METHOD TO PREVENT VISION LOSS | QLT, INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| EP-1229937-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT Inc. (CA) | 2002-08-14 | — | — | EP | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001085213-A2 | SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085212-A2 | DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001035996-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001035997-A2 | USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | MAPK1 4750/4885KMT2A 2286/4885YEATS4 4663/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | MAPK1 4556/4885KMT2A 2520/4885YEATS4 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.